BIOMAT Database Logo BIOMAT Database Logo

Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine. 1979

V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward

Randomized clinical trials in 300 patients undergoing major abdominal surgery or hip replacement arthroplasty were performed to investigate the efficacy of dihydroergotamine mesylate, heparin calcium, or a combination of dihydroergotamine with heparin in preventing postoperative deep-vein thrombosis (DVT). The diagnosis of DVT was established by an uptake test using fibrinogen labeled with iodine 125; in patients undergoing hip replacement, phlebography was also employed to confirm or refute the presence of isotopic thrombi. The data indicate that the combination of dihydroergotamine and heparin is more effective than heparin or dihydroergotamine alone in preventing DVT.

UI MeSH Term Description Entries
D007866 Leg The inferior part of the lower extremity between the KNEE and the ANKLE. Legs
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D004087 Dihydroergotamine A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. Agit,Angionorm,Clavigrenin,D-Tamin Retard L.U.T.,D.H.E. 45,DET MS,DHE-45,DHE-Puren,DHE-Ratiopharm,Dihydergot,Dihydroergotamin AL,Dihydroergotamine Mesylate,Dihydroergotamine Methanesulfonate,Dihydroergotamine-Sandoz,Dihytamin,Erganton,Ergomimet,Ergont,Ergotam Von Ct,Ikaran,Migranal,Orstanorm,Seglor,Tamik,Verladyn,D Tamin Retard L.U.T.,DHE 45,DHE Puren,DHE Ratiopharm,DHE45,Dihydroergotamine Sandoz,Mesylate, Dihydroergotamine,Methanesulfonate, Dihydroergotamine,Von Ct, Ergotam
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis.
February 1985, JAMA,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis.
September 1986, The British journal of surgery,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Dihydroergotamine-heparin to prevent postoperative deep vein thrombosis.
May 1985, The Medical letter on drugs and therapeutics,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Combined dihydroergotamine and heparin prophylaxis of postoperative deep vein thrombosis: proposed mechanism of action.
October 1985, American journal of surgery,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Dihydroergotamine-heparin prophylaxis of postoperative deep vein thrombosis. A multicenter trial. The Multicenter Trial Committee.
June 1984, JAMA,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
United States trial of dihydroergotamine and heparin prophylaxis of deep vein thrombosis.
October 1985, American journal of surgery,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Postoperative deep-vein thrombosis. Effect of intensive prophylaxis.
March 1969, Lancet (London, England),
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Limitation of impedance plethysmography in assessing efficacy of dihydroergotamine-heparin prophylaxis of deep vein thrombosis.
February 1985, Thrombosis research,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Heparin prophylaxis for deep vein thrombosis and pulmonary embolism.
September 1976, The Western journal of medicine,
V V Kakkar, and J D Stamatakis, and P G Bentley, and D Lawrence, and H A de Haas, and V P Ward
Subcutaneous heparin and postoperative deep-vein thrombosis.
October 1972, Lancet (London, England),
Copied contents to your clipboard!